Patents by Inventor Chonghui Zhang

Chonghui Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BCMA chimeric antigen receptors and uses thereof
    Patent number: 11952428
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: April 9, 2024
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • BCMA chimeric antigen receptors and uses thereof
    Patent number: 11939389
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: March 26, 2024
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20230416390
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: March 16, 2023
    Publication date: December 28, 2023
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20230250179
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 10, 2023
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20230183368
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: February 17, 2023
    Publication date: June 15, 2023
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • BCMA chimeric antigen receptors and uses thereof
    Patent number: 11608382
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 21, 2023
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
    Publication number: 20220364055
    Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 17, 2022
    Inventors: Louise Treanor, Michael R. Greene, Jennifer Brogdon, Boris Engels, Glenn Dranoff, Olja Kodrasi, Hyungwook Lim, Akash Sohoni, Elizabeth Dorothy Pratico, Anniesha Hack, Aida Abujoub, Tony Fleming, Lu Huang, Connie Hong, John Blankenship, Brian Holmberg, Chonghui Zhang, Dexiu Bu, Andrew Price, Xu Zhu, Andrew Stein, Attilio Bondanza
  • CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20210220404
    Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.
    Type: Application
    Filed: November 25, 2020
    Publication date: July 22, 2021
    Inventors: Aida Abujoub, John Blankenship, Attilio Bondanza, Jennifer Brogdon, Dexiu Bu, Serena De Vita, Glenn Dranoff, Boris Engels, Tony Fleming, Brian Walter Granda, Michael R. Greene, Carla Patricia Guimaraes, Anniesha Hack, Brian Holmberg, Connie Hong, Lu Huang, Olja Kodrasi, Joni Waiee Lam, Hyungwook Lim, Elizabeth Dorothy Pratico, Andrew Price, Akash Sohoni, Andrew Marc Stein, Louise Treanor, Chonghui Zhang, Xu Zhu
  • Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 10870698
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 22, 2020
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20190382500
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 19, 2019
    Inventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20190040128
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: May 4, 2018
    Publication date: February 7, 2019
    Applicant: NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodies
    Patent number: 9982046
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 29, 2018
    Assignee: NOVARTIS AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20170152313
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 1, 2017
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • Lectin-like oxidized LDL receptor 1 antibodies and methods of use
    Patent number: 9512222
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 6, 2016
    Assignee: Novartis AG
    Inventors: Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
  • ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
    Publication number: 20150274824
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferrentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.
    Type: Application
    Filed: February 19, 2015
    Publication date: October 1, 2015
    Inventors: Veronique BLANC, Claudia FROMAND, Fabienne PARKER, Jiawen HAN, Daniel TAVARES, Chonghui ZHANG, Min LI, Xiao-Mai ZHOU, Michel STREULI
  • Methods of use for antibodies that specifically bind to the EphA2 receptor
    Patent number: 8992912
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: March 31, 2015
    Assignee: Sanofi
    Inventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
  • LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE
    Publication number: 20150004168
    Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
    Type: Application
    Filed: June 18, 2014
    Publication date: January 1, 2015
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Kurt Alex HELDWEIN, Igor SPLAWSKI, Jennifer BROGDON, Joshua GOLDSTEIN, William DOLE, John TRAUGER, Chonghui ZHANG
  • ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
    Publication number: 20130302316
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.
    Type: Application
    Filed: March 6, 2013
    Publication date: November 14, 2013
    Inventors: Veronique BLANC, Claudia FROMOND, Fabienne PARKER, Jiawen HAN, Daniel TAVARES, Chonghui ZHANG, Min LI, Xiao-Mai ZHOU, Michel STREULI
  • EPHA2 receptor antagonist antibodies
    Patent number: 8460667
    Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: June 11, 2013
    Assignee: Sanofi
    Inventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
  • EPHA2 receptor antagonist antibodies
    Patent number: RE47123
    Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: November 13, 2018
    Assignee: SANOFI
    Inventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli